After Statins, What Next?
This article was originally published in Start Up
As statins go generic, a host of companies are hunting out new treatments for cholesterol control. They're not put off by recent setbacks, given the huge remaining unmet need and commercial opportunity. Many new companies are still trying to lower LDL and/or raise HDL, but anti-inflammatory approaches are increasingly popular too, as scientists better understand the nature and process of plaque formation.
You may also be interested in...
Sanofi will lose exclusivity for Plavix, Avapro and Eloxatin in 2012, driving what it expects will be a 12% to 15% EPS decline, but management is counting on a new wave of drugs – and the addition of Genzyme – to return to growth.
Current treatments for atherosclerosis use markers and therapeutic targets that are consequences of the disease. Aterovax SA is attempting a more direct route. By basing its research and pipeline on sPLA2, a family of secreted phospholipases that are mediators in the inflammatory process involved in atherosclerosis, it hopes to create products that are either predictive of cardiovascular disease rather than simply diagnostic, or that can stop the development of unstable atherosclerotic plaques.
Despite several setbacks this year, and a major competitor's withdrawal from further R&D in the field, Merck reiterated its commitment to cardiovascular R&D at its annual business review Dec. 9 and outlined an aggressive cardiovascular development program